Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124876 | 0.85 | SIGMAR1 (0.57) | CCR8SIGMAR1 | |
| SCHEMBL5125338 | 0.85 | NMT2 (0.44) | — | |
| SCHEMBL5188756 | 0.85 | NMT2 (0.44) | — | |
| SCHEMBL5130455 | 0.83 | BCHE (0.49) | CCR8SIGMAR1SMN1; SMN2KDM4ECYP2C19 | |
| SCHEMBL5117306 | 0.83 | CCR8 (0.47) | CCR8SIGMAR1SMN1; SMN2CYP2C19USP2 | |
| SCHEMBL5118332 | 0.82 | CCR8 (0.47) | CCR8SIGMAR1SMN1; SMN2CYP2C19USP2 | |
| SCHEMBL5165517 | 0.82 | CCR8 (0.46) | CCR8SIGMAR1SMN1; SMN2CYP2C19USP2 | |
| SCHEMBL5127760 | 0.81 | SIGMAR1 (0.51) | SIGMAR1SMN1; SMN2 | |
| SCHEMBL5126563 | 0.81 | CCR2 (0.53) | SMN1; SMN2 | |
| SCHEMBL5121666 | 0.79 | CYP2C19 (0.53) | SIGMAR1SMN1; SMN2CYP2C19CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | claimed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | disclosed |
| EP-1768955-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006005941-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | CCR8 2140/4885SIGMAR1 4156/4885SMN1; SMN2 2901/4885 |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC4 | CCR8 4539/4885SIGMAR1 3350/4885SMN1; SMN2 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.